Pharmacokinetics of a topical application of moxidectin in bare-nosed wombats (Vombatus ursinus).
Blood
Cydectin®
Plasma
Sarcoptes scabiei
Sarcoptic mange
Scat
Journal
Veterinary parasitology, regional studies and reports
ISSN: 2405-9390
Titre abrégé: Vet Parasitol Reg Stud Reports
Pays: Netherlands
ID NLM: 101680410
Informations de publication
Date de publication:
Aug 2024
Aug 2024
Historique:
received:
22
02
2024
revised:
12
06
2024
accepted:
24
06
2024
medline:
19
7
2024
pubmed:
19
7
2024
entrez:
18
7
2024
Statut:
ppublish
Résumé
Sarcoptic mange is a debilitating disease that affects bare-nosed wombats (Vombatus ursinus). One of the drugs currently used for treatment is moxidectin, as it has a relatively high efficacy against endo and ectoparasites and side effects are uncommon in domestic species, thus it is considered a relatively safe drug to use at the recommended doses. Developing further understanding of the pharmacokinetics of moxidectin will aid in developing treatment regimens for sarcoptic mange in wombats. Here we analyzed the pharmacokinetic parameters of using 100 ml of moxidectin (5 g/l) applied topically. We found that mean peak plasma concentration was 0.50 ng/ml and half-life was 8 days. Moxidectin was excreted in scats with the mean peak concentration of 2461.43 ng/g (on a dry matter basis). Our study has provided the pharmacokinetic parameters of a commonly used treatment for sarcoptic mange in wombats. There were no adverse side effects recorded in the wombats after applying moxidectin topically. This study replicated real-world conditions using topical application on free-living wombats. The relatively low plasma concentration suggests the drug is not accumulating in the blood stream and is excreted via scats.
Identifiants
pubmed: 39025544
pii: S2405-9390(24)00094-7
doi: 10.1016/j.vprsr.2024.101074
pii:
doi:
Substances chimiques
moxidectin
NGU5H31YO9
Macrolides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
101074Informations de copyright
Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Hayley Stannard reports financial support was provided by Wombat Protection Society of Australia. Marie Wynan reports a relationship with Wombat Protection Society of Australia that includes: board membership. Amanda Cox reports a relationship with Wombat Protection Society of Australia that includes: board membership. The other authors, declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.